Welcome to our dedicated page for Resmed SEC filings (Ticker: RSMDF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Resmed's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Resmed's regulatory disclosures and financial reporting.
RESMED INC Chairman and CEO Michael J. Farrell reported an exercise-and-sale transaction in company stock. On June 8, 2026, he exercised options to acquire 4,991 shares of ResMed Common Stock at $146.34 per share and sold the same 4,991 shares in open-market trades at a $193.962 weighted average price. The sales were executed in multiple trades between $192.605 and $194.715 under a pre-arranged Rule 10b5-1 plan adopted October 31, 2024. Following these transactions, he directly held 466,256 ResMed shares, with 2,090 shares held indirectly through the Lisette and Michael Farrell Family Trust and 24,957 stock options remaining outstanding.
RESMED INC Chairman and CEO Michael J. Farrell reported an exercise-and-sale transaction in company stock. On June 8, 2026, he exercised options to acquire 4,991 shares of ResMed Common Stock at $146.34 per share and sold the same 4,991 shares in open-market trades at a $193.962 weighted average price. The sales were executed in multiple trades between $192.605 and $194.715 under a pre-arranged Rule 10b5-1 plan adopted October 31, 2024. Following these transactions, he directly held 466,256 ResMed shares, with 2,090 shares held indirectly through the Lisette and Michael Farrell Family Trust and 24,957 stock options remaining outstanding.
RMD reported a Form 144 notice for the sale of 4,991 shares of Common Stock via a stock option exercise on 06/08/2026. The filing lists three prior monthly dispositions of 4,991 shares each on 03/09/2026, 04/07/2026, and 05/07/2026 with cash proceeds shown.
RMD reported a Form 144 notice for the sale of 4,991 shares of Common Stock via a stock option exercise on 06/08/2026. The filing lists three prior monthly dispositions of 4,991 shares each on 03/09/2026, 04/07/2026, and 05/07/2026 with cash proceeds shown.
ResMed Inc Global General Counsel Michael J. Rider reported a small tax-related share disposition. On June 1, 2026, 268.742 shares of ResMed common stock were surrendered at $190.57 per share to cover tax withholding on the vesting of Restricted Stock Units that were granted on June 1, 2023. This was a tax-withholding mechanism, not an open-market sale. After this transaction, Rider directly holds 9,488 shares of ResMed common stock, which includes 66.0288 shares purchased on April 30, 2026 through the ResMed Employee Stock Purchase Plan.
ResMed Inc Global General Counsel Michael J. Rider reported a small tax-related share disposition. On June 1, 2026, 268.742 shares of ResMed common stock were surrendered at $190.57 per share to cover tax withholding on the vesting of Restricted Stock Units that were granted on June 1, 2023. This was a tax-withholding mechanism, not an open-market sale. After this transaction, Rider directly holds 9,488 shares of ResMed common stock, which includes 66.0288 shares purchased on April 30, 2026 through the ResMed Employee Stock Purchase Plan.
Issuer filed a Form 144 reporting proposed resale and recent dispositions of common stock. The filing lists 8,000 shares associated with Fidelity Brokerage Services LLC with an aggregate value of $1,672,560.00 and two disclosed past sales by Brett Sandercock of 1,000 shares on 03/02/2026 for $254,300.00 and 1,000 shares on 04/01/2026 for $224,310.00. The securities are noted as from Restricted Stock Vesting dated 11/21/2019.
Issuer filed a Form 144 reporting proposed resale and recent dispositions of common stock. The filing lists 8,000 shares associated with Fidelity Brokerage Services LLC with an aggregate value of $1,672,560.00 and two disclosed past sales by Brett Sandercock of 1,000 shares on 03/02/2026 for $254,300.00 and 1,000 shares on 04/01/2026 for $224,310.00. The securities are noted as from Restricted Stock Vesting dated 11/21/2019.
ResMed Inc.’s Chairman and CEO Michael J. Farrell reported a same-day option exercise and share sale in ResMed common stock. He exercised options to acquire 4,991 shares at $146.34 per share, then sold 4,991 shares in an open-market transaction at a weighted average price of $207.8206 per share.
After the sale, Farrell directly holds 466,223 ResMed shares and indirectly holds 2,090 shares through the Lisette and Michael Farrell Family Trust. The transactions were conducted on May 7, 2026 under a pre-arranged Rule 10b5-1 trading plan adopted on October 31, 2024, indicating a scheduled, routine disposition rather than ad hoc trading.
ResMed Inc.’s Chairman and CEO Michael J. Farrell reported a same-day option exercise and share sale in ResMed common stock. He exercised options to acquire 4,991 shares at $146.34 per share, then sold 4,991 shares in an open-market transaction at a weighted average price of $207.8206 per share.
After the sale, Farrell directly holds 466,223 ResMed shares and indirectly holds 2,090 shares through the Lisette and Michael Farrell Family Trust. The transactions were conducted on May 7, 2026 under a pre-arranged Rule 10b5-1 trading plan adopted on October 31, 2024, indicating a scheduled, routine disposition rather than ad hoc trading.
Michael Farrell reported a proposed sale of 4,991 shares of Common Stock under Rule 144 on 05/07/2026. The form lists an option granted dated 11/21/2019 and shows three prior sales of 4,991 shares on 02/09/2026, 03/09/2026, and 04/07/2026 with dollar figures provided alongside each sale.
Michael Farrell reported a proposed sale of 4,991 shares of Common Stock under Rule 144 on 05/07/2026. The form lists an option granted dated 11/21/2019 and shows three prior sales of 4,991 shares on 02/09/2026, 03/09/2026, and 04/07/2026 with dollar figures provided alongside each sale.
RESMED INC executive Aaron Bloomer, the company’s Chief Financial Officer, filed an initial statement of beneficial ownership on Form 3. This filing establishes his status as a reporting insider of ResMed but does not list any equity holdings or report any buy or sell transactions.
RESMED INC executive Aaron Bloomer, the company’s Chief Financial Officer, filed an initial statement of beneficial ownership on Form 3. This filing establishes his status as a reporting insider of ResMed but does not list any equity holdings or report any buy or sell transactions.
ResMed Inc.’s Chief Financial Officer Brett Sandercock reported his direct ownership of ResMed Common Stock. Following the reported information, he directly holds 83,495 shares of common stock. The filing reflects his updated ownership position without detailing any specific buy or sell transaction.
ResMed Inc.’s Chief Financial Officer Brett Sandercock reported his direct ownership of ResMed Common Stock. Following the reported information, he directly holds 83,495 shares of common stock. The filing reflects his updated ownership position without detailing any specific buy or sell transaction.
ResMed Inc. announced a planned chief financial officer transition. Long‑tenured CFO Brett Sandercock will retire from the CFO role effective May 4, 2026 and move into special advisory positions to support Chairman and CEO Mick Farrell during the leadership handover.
The company appointed Aaron Bloomer, formerly CFO of Exact Sciences, as the new Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, effective May 4, 2026. His package includes a $725,000 base salary, a $150,000 sign‑on bonus, and a $3.3 million sign‑on equity grant split between restricted stock units and performance stock units.
ResMed also reported third‑quarter fiscal 2026 results and reiterated its fiscal 2026 outlook, including a gross margin range of 62–63%, SG&A expenses of 19–20%, R&D expenses of 6–7%, and an effective tax rate of 21–23%.
ResMed Inc. announced a planned chief financial officer transition. Long‑tenured CFO Brett Sandercock will retire from the CFO role effective May 4, 2026 and move into special advisory positions to support Chairman and CEO Mick Farrell during the leadership handover.
The company appointed Aaron Bloomer, formerly CFO of Exact Sciences, as the new Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, effective May 4, 2026. His package includes a $725,000 base salary, a $150,000 sign‑on bonus, and a $3.3 million sign‑on equity grant split between restricted stock units and performance stock units.
ResMed also reported third‑quarter fiscal 2026 results and reiterated its fiscal 2026 outlook, including a gross margin range of 62–63%, SG&A expenses of 19–20%, R&D expenses of 6–7%, and an effective tax rate of 21–23%.
ResMed Inc. reported strong third-quarter fiscal 2026 results and declared a cash dividend. Net revenue was $1.43 billion, up 11% from $1.29 billion a year earlier, with GAAP net income of $398.7 million and diluted EPS of $2.74.
Non-GAAP diluted EPS was $2.86, up from $2.37. Operating cash flow for the quarter was $554.1 million, and cash and cash equivalents were $1.66 billion as of March 31, 2026. The board declared a quarterly dividend of $0.60 per share, with a record date of May 14, 2026 and payment on June 18, 2026.
ResMed Inc. reported strong third-quarter fiscal 2026 results and declared a cash dividend. Net revenue was $1.43 billion, up 11% from $1.29 billion a year earlier, with GAAP net income of $398.7 million and diluted EPS of $2.74.
Non-GAAP diluted EPS was $2.86, up from $2.37. Operating cash flow for the quarter was $554.1 million, and cash and cash equivalents were $1.66 billion as of March 31, 2026. The board declared a quarterly dividend of $0.60 per share, with a record date of May 14, 2026 and payment on June 18, 2026.